期刊
BREAST CANCER RESEARCH AND TREATMENT
卷 146, 期 1, 页码 211-220出版社
SPRINGER
DOI: 10.1007/s10549-014-2991-x
关键词
Mutation load; Breast cancer; DNA damage repair; Estrogen receptor
类别
资金
- Cancer Center Support Grant [5 P30 CA016672-38]
- Norman Brinker Award for Research Excellence
- John Charles Cain Distinguished Chair Award
- Mariam Rogers Fund for Breast/Women's Cancer Research
- University of Texas MD Anderson Cancer Center Halliburton Fellowship in Cancer Prevention Fund
Breast cancer is one of the most commonly diagnosed cancers in women. While there are several effective therapies for breast cancer and important single gene prognostic/predictive markers, more than 40,000 women die from this disease every year. The increasing availability of large-scale genomic datasets provides opportunities for identifying factors that influence breast cancer survival in smaller, well-defined subsets. The purpose of this study was to investigate the genomic landscape of various breast cancer subtypes and its potential associations with clinical outcomes. We used statistical analysis of sequence data generated by the Cancer Genome Atlas initiative including somatic mutation load (SML) analysis, Kaplan-Meier survival curves, gene mutational frequency, and mutational enrichment evaluation to study the genomic landscape of breast cancer. We show that ER+, but not ER-, tumors with high SML associate with poor overall survival (HR = 2.02). Further, these high mutation load tumors are enriched for coincident mutations in both DNA damage repair and ER signature genes. While it is known that somatic mutations in specific genes affect breast cancer survival, this study is the first to identify that SML may constitute an important global signature for a subset of ER+ tumors prone to high mortality. Moreover, although somatic mutations in individual DNA damage genes affect clinical outcome, our results indicate that coincident mutations in DNA damage response and signature ER genes may prove more informative for ER+ breast cancer survival. Next generation sequencing may prove an essential tool for identifying pathways underlying poor outcomes and for tailoring therapeutic strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据